Descripción de negocio
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Consejo de gestión & Consejo de supervisión
| CEO |
| Naoki Okamura |
| Consejo de gestión |
| Atsushi Kitamura, Katsuyoshi Sugita, Yoshitsugu Shitaka, Tadaaki Taniguchi, Hideki Shima, Claus Zieler, Adam Pearson, Catherine Levitt |
| Consejo de supervisión |
| Kenji Yasukawa, Naoki Okamura, Katsuyoshi Sugita, Takashi Tanaka, Eriko Sakurai, Masahiro Miyazaki, Yoichi Ohno, Toru Yoshimitsu, Raita Takahashi, Mika Nakayama, Rie Akiyama |
Datos de la empresa
| Nombre: |
Astellas Pharma Inc. |
| Dirección: |
2-5-1, Nihonbashi-Honcho,Chuo-Ku, Tokyo 103-8411 |
| Teléfono: |
+81-3-3244-3000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.astellas.com/en/ |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
- |
| Fin del año financiero: |
31/03 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
- |
Relación con inversores
| Nombre: |
- |
| IR teléfono: |
+81-3-3244-3202 |
| IR-fax: |
- |
| IR e-mail: |
-
|
